Disc Medicine (IRON) Stock Forecast & Price Target

$62.55 +3.00 (+5.04%)

(As of 11/20/2024 ET)

Disc Medicine - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 10 Analyst Ratings

Sell
0

Hold
0

Buy
10

Based on 10 Wall Street analysts who have issued ratings for Disc Medicine in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 9 have given a buy rating, and 1 has given a strong buy rating for IRON.

Consensus Price Target

$85.80
37.17% Upside

According to the 10 analysts' twelve-month price targets for Disc Medicine, the average price target is $85.80. The highest price target for IRON is $118.00, while the lowest price target for IRON is $70.00. The average price target represents a forecasted upside of 37.17% from the current price of $62.55.

Get the Latest News and Ratings for IRON and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Disc Medicine and its competitors.

IRON Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	9 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	9 Buy rating(s)
Hold	0 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$85.80	$63.89	$64.13	$59.22
Forecasted Upside	37.17% Upside	25.47% Upside	29.78% Upside	13.89% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Buy

Trump said you could learn something from this man (Ad)

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

Here’s everything you need to know.

IRON Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IRON Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Disc Medicine Stock vs. The Competition

Type	Disc Medicine	Medical Companies	S&P 500
Consensus Rating Score	3.10	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	37.17% Upside	26,931.57% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent IRON News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/13/2024	HC Wainwright 2 of 5 stars		Boost Target	Buy ➝ Buy	$70.00 ➝ $118.00	+89.95%
11/12/2024	Wedbush 4 of 5 stars		Reiterated Rating	Outperform	$75.00 ➝ $83.00	+31.20%
11/5/2024	Scotiabank 5 of 5 stars	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Outperform ➝ Sector Outperform	$62.00 ➝ $70.00	+8.07%
11/5/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$85.00	+45.92%
11/4/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$66.00 ➝ $110.00	+95.73%
10/23/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$89.00	+74.78%
[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad) All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin
10/15/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$85.00 ➝ $85.00	+77.23%
8/22/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Fauth Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$75.00	+52.10%
6/17/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$50.00 ➝ $70.00	+51.29%
4/8/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$71.00 ➝ $73.00	+144.31%
4/24/2023	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Katkhuda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/28/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00	+47.60%
2/28/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$36.00	+47.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:37 AM ET.

IRON Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Disc Medicine is $85.80, with a high forecast of $118.00 and a low forecast of $70.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Disc Medicine in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRON shares.
: According to analysts, Disc Medicine's stock has a predicted upside of 37.17% based on their 12-month stock forecasts.
: Over the previous 90 days, Disc Medicine's stock had 2 upgrades by analysts.
: Disc Medicine has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group, Morgan Stanley, Raymond James, Scotiabank, and Wedbush in the past 90 days.
: Analysts like Disc Medicine more than other "medical" companies. The consensus rating for Disc Medicine is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IRON compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump won. Buy this coin now. (Ad)

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

This page (NASDAQ:IRON) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Disc Medicine (IRON) Stock Forecast & Price Target